Medscape2d
European Commission Approves Nemolizumab for Atopic Dermatitis and Prurigo Nodularis
The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...
Healio2d
Nemluvio approved in EU, UK, Switzerland for atopic dermatitis, prurigo nodularis
Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...
PMLiVE3d
EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis
Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...
GlobalData on MSN7d
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Business Wire7d
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...
Galderma's Nemluvio® (Nemolizumab) Approved In The European Union For Moderate-To-Severe Atopic Dermatitis And Prurigo N...
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...
AFP7d
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Nemluvio is also approved by the U.S. Food and Drug Administration for the treatment of atopic dermatitis and prurigo nodularis. 12 It is under review for the treatment of both diseases by several ...